ThinkEquity jumps into biotech as rivals flee – Tough research project

It’s not as simple as it used to be by all means as it’s difficult to predict a science, and that is what biotech is, now combining and merging with clinical applications and tests, so the waters get a bit muddy, and you can’t research R and D as much as we would like to. Biotech is also much more diversified today with the use of genomics and RNAs to determine protein properties and how to design a drug based on the expressions derived, but genomics is definitely helping to lay out the game plan. BD

BOSTON, Jan. 23 (Reuters) - ThinkEquity LLC is forming a new healthcare group as it seeks to take advantage of turmoil in the biotechnology sector.

The firm is putting together a new team of healthcare analysts and bankers at a time Wall Street is shedding jobs and the biotech sector is on the brink of implosion.

Of the country's 400 public biotech companies, roughly 75 percent have less than one year of cash, and 120 of those have less than six months of cash, according to Burrill & Company, a specialist life science bank.

ThinkEquity jumps into biotech as rivals flee | Markets | Markets News | Reuters